1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. ArQule Acquires Cyclis Pharmaceuticals

M&A Deal Summary

ArQule Acquires Cyclis Pharmaceuticals

On July 17, 2003, ArQule acquired life science company Cyclis Pharmaceuticals for 25M USD

Acquisition Highlights
  • This is ArQule’s 2nd transaction in the Life Science sector.
  • This is ArQule’s 2nd largest (disclosed) transaction.
  • This is ArQule’s 2nd transaction in the United States.
  • This is ArQule’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2003-07-17
Target Cyclis Pharmaceuticals
Sector Life Science
Buyer(s) ArQule
Deal Type Add-on Acquisition
Deal Value 25M USD

Target

Cyclis Pharmaceuticals

Norwood, Massachusetts, United States
Cyclis is discovering and developing small-molecule cancer drugs based on a novel technology designed to selectively kill cancer cells and preserve normal cells by restoring and activating cellular checkpoints known to be defective in cancers.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

ArQule

Burlington, Massachusetts, United States
Category Company
Founded 1993
Sector Life Science
Employees38
Revenue 26M USD (2018)
DESCRIPTION

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. ArQule's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule was formed in 1993 and is based in Burlington, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: Massachusetts M&A 1 of 1
Country: United States M&A 2 of 2
Year: 2003 M&A 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2001-01-29 Camitro

Menlo Park, California, United States

Camitro Corp., is a predictive modeling company. Camitro's technology consisted of an integrated platform of predictive models and strategies for the design, selection, and optimization of potential new pharmaceutical drugs.

Buy $76M
Mergr

Solution for

Product

Company

Legal